Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    48,632.41
    -1,630.67 (-3.24%)
     
  • CMC Crypto 200

    1,261.13
    -96.88 (-7.13%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

In Vitro Diagnostics Business Outlook 2022: Twice-Monthly Publication Dedicated to IVD

Company Logo
Company Logo

Dublin, May 04, 2022 (GLOBE NEWSWIRE) -- The "In Vitro Diagnostics Business Outlook" newsletter has been added to ResearchAndMarkets.com's offering.

The twice-monthly publication dedicated to IVD, In Vitro Diagnostics Business Outlook will offer the following:

  • Market Sizing and Forecasting of IVD Market Segments in Every Issue

  • Clinical Chemistry, Infectious Disease Testing, Oncology, Hematology, Blood Banking, Coagulation, Point of Care-Updates on the Important Test Categories You Need to Know About

  • Industry Watch - Developments with COVID-19 and Other Testing

  • M&A, Distribution, Partnerships Tracked and Charted

  • New Product Introductions and Company Announcements

  • Company Profiling and Quarterly Results Summaries

  • Regional Market Coverage

For more information about this newsletter visit https://www.researchandmarkets.com/r/39it8x

ADVERTISEMENT
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900